Key Takeaways
- • Sharp Biomedical, a medical device company developing manual spine procedures for outpatient pain clinics, has closed a pre-seed funding round led by gener8tor 1889, a North Dakota venture capital fund, according to a PR Newswire release.
- • The round included participation from several physician angel investors, and the company said the capital will fully fund its development and testing pathway toward a first purpose-built toolset and implant system.
- • The company is targeting early-to-mid-stage chronic pain patients with procedures designed to run in outpatient settings without large capital expenditures, hospital infrastructure, or robotics.
- • Founder and CEO Dan Newman said the funding positions Sharp for its next regulatory milestones and the eventual commercial launch of its flagship device.
- • The round size was not disclosed in the source material.
Summary
Sharp Biomedical has announced the closing of its pre-seed funding round, led by gener8tor 1889, the North Dakota-focused venture capital fund operated by gener8tor. Physician angel investors also participated. According to the company's announcement, the new capital will fully fund the development and testing pathway needed to bring the company's first purpose-built toolset and implant system to market. The company did not disclose the round size in the material reviewed.
Sharp Biomedical describes itself as a medical device company focused on streamlined toolsets and implants for spinal care. Its approach centers on safe, manual procedures that can be performed in less operating time within outpatient pain clinics, which the company says reduces the industry's reliance on large hospital infrastructure, robotics, and prolonged operating times. The technology is designed to fit the workflow of outpatient pain clinics and targets early-to-mid-stage chronic pain patients.
Dan Newman, Founder and CEO of Sharp Biomedical, said the industry is focused on advanced robotics and complex technologies for late-stage spinal care, while the company sees an unmet need earlier in the care continuum. Ben Stanley, Principal of gener8tor 1889, praised Newman and the team and said the company's mission to democratize access to spine care is a differentiated approach in a complex industry. Stanley also cited the company's commitment to growing the North Dakota biotech ecosystem. Dr. Danny Neuman, an interventional pain specialist and advisor to Sharp, said the company's physician-informed design process addresses real clinical needs.
With funding secured, Sharp Biomedical says it is advancing its testing protocols and physician input ahead of regulatory milestones and an eventual commercial launch of its flagship device. gener8tor is a global venture firm and accelerator network operating programs in more than 41 communities across 22 states and two countries.
Sharp Biomedical describes itself as a medical device company focused on streamlined toolsets and implants for spinal care. Its approach centers on safe, manual procedures that can be performed in less operating time within outpatient pain clinics, which the company says reduces the industry's reliance on large hospital infrastructure, robotics, and prolonged operating times. The technology is designed to fit the workflow of outpatient pain clinics and targets early-to-mid-stage chronic pain patients.
Dan Newman, Founder and CEO of Sharp Biomedical, said the industry is focused on advanced robotics and complex technologies for late-stage spinal care, while the company sees an unmet need earlier in the care continuum. Ben Stanley, Principal of gener8tor 1889, praised Newman and the team and said the company's mission to democratize access to spine care is a differentiated approach in a complex industry. Stanley also cited the company's commitment to growing the North Dakota biotech ecosystem. Dr. Danny Neuman, an interventional pain specialist and advisor to Sharp, said the company's physician-informed design process addresses real clinical needs.
With funding secured, Sharp Biomedical says it is advancing its testing protocols and physician input ahead of regulatory milestones and an eventual commercial launch of its flagship device. gener8tor is a global venture firm and accelerator network operating programs in more than 41 communities across 22 states and two countries.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.